Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Any hopes of differentiation could come down to side effects.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
The Breakwater study hits on overall survival with "unprecedented" data.
Crunch time approaches for UroGen.
The combined company's MALT1 inhibitor has started phase 1.
